A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis.
NCT ID: NCT05689151
Last Updated: 2025-12-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
183 participants
OBSERVATIONAL
2023-03-09
2027-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study is seeking participant who are older than 18 years with moderate-to-severe chronic AD. Participants must have no underlying medical conditions that prevent them from taking Abrocitinib.
All participants in this study will receive Abrocitinib as a tablet once daily. They can take Abrocitinib and use medicated topical treatment for AD at the same time.
We will examine the experiences of patients receiving the study medicine. This will help us determine if the study medicine is safe and helps in treating AD.
Participants will take part in this study for 24 months. During this time, they will visit the study clinic about 5 times (about 1 time every 4 to 6 months).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
NCT05250115
Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
NCT03422822
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
NCT06807281
Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy
NCT04345367
Study Evaluating the Mechanism of Action of PF-04965842 Monotherapy for Moderate-to-severe Atopic Dermatitis
NCT03915496
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Abrocitinib
Study Drug for Observational Data Collection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with clinical diagnosis of moderate-to-severe chronic atopic dermatitis (also referred to as atopic eczema) at inclusion according to the investigator and eligible for abrocitinib according to its marketing approval.
* Patients that have been informed of the study procedures and have signed the consent.
Exclusion Criteria
* Patients unable to follow and respect the study procedures and judged inapt to respond to the questions required for the study due to linguistical, psychological, social, or geographical reasons.
* Patients not affiliated to the French social security system.
* Patients deprived of liberty, under guardianship, or unable to provide oral consent.
* Patients participating in a clinical study assessing a medicinal treatment (patients can participate in registries and observatories).
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Amiens-Picardie - Site Nord
Amiens, Somme, France
CHU Besancon - Hopital Jean Minjoz
Besançon, , France
Polyclinique Reims Bezannes
Bezannes, , France
Chu Bordeaux Hopital Saint Andre
Bordeaux, , France
CHU Brest Hopital Morvan
Brest, , France
CHU de Caen
Caen, , France
Ch de Calais
Calais, , France
Ch William Morey
Chalon-sur-Saône, , France
CHU Clermont Ferrand - Hopital Gabriel Montpied
Clermont-Ferrand, , France
Chu Estaing
Clermont-Ferrand, , France
Hopital Henri Mondor
Créteil, , France
Chu Dijon
Dijon, , France
Hopital Franco Britannique
Levallois-Perret, , France
Hopital Claude Huriez
Lille, , France
CH de Martigues
Martigues, , France
CHU Montpellier
Montpellier, , France
Hopital Emile Muller
Mulhouse, , France
Hopital Hotel Dieu
Nantes, , France
Hopital Cochin
Paris, , France
Hopital Tenon
Paris, , France
Hopital Saint Louis (APHP) - Service Hematologic Senior
Paris, , France
CHU Lyon Sud
Pierre-Bénite, , France
Hopital Pontchaillou
Rennes, , France
Ch de Romans Sur Isere
Romans-sur-Isère, , France
Hopital Charles Nicolle
Rouen, , France
Chi Poissy Saint Germain En Laye
Saint-Germain-en-Laye, , France
Hopital Bégin
Saint-Mandé, , France
Hopital Larrey
Toulouse, , France
Ch de Valenciennes
Valenciennes, , France
CHU Nancy
Vandœuvre-lès-Nancy, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ADAIR
Identifier Type: OTHER
Identifier Source: secondary_id
B7451096
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.